NCT07004257View on ClinicalTrials.gov

ButOx Human Trial: An Open Label Prospective Cohort Study to Investigate the Effect of Tributyrin (Butyrate Precursor Molecule) Supplementation on Markers of Calcium Oxalate Nephrolithiasis

NANot yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
Urolithiasis
Interventions
DIETARY_SUPPLEMENT

tributyrin

tributyrin (875 mg, BID)

Trial Locations (1)

V5Z1M9

Vancouver General Hospital, Vancouver

All Listed Sponsors
lead

University of British Columbia

OTHER